(HRMY) Harmony Biosciences Holdings - Ratings and Ratios
Medication, Wakix, Narcolepsy Treatment
HRMY EPS (Earnings per Share)
HRMY Revenue
Description: HRMY Harmony Biosciences Holdings
Harmony Biosciences Holdings (NASDAQ:HRMY) is a US-based pharmaceutical company. The companys market capitalization stands at approximately $2.04 billion, indicating a moderate size within the industry. Its stock is classified as a common stock, providing shareholders with ownership rights.
The pharmaceutical sub-industry is characterized by high research and development costs, stringent regulatory requirements, and significant competition. Harmonys performance can be evaluated through key metrics such as Return on Equity (ROE), which is reported at 24.29%, suggesting a relatively strong ability to generate profits from shareholder equity.
The companys valuation multiples, including a Price-to-Earnings (P/E) ratio of 13.11 and a forward P/E of 9.29, indicate the markets expectations for its future earnings growth. These multiples are relatively moderate, suggesting that the stock may be reasonably valued compared to its earnings.
Key economic drivers for Harmony Biosciences include the demand for its pharmaceutical products, the success of its research and development pipeline, and the competitive landscape within the industry. The companys ability to manage its cost structure, including research and development expenses, sales and marketing costs, and general administrative expenses, will also be crucial in determining its profitability.
To further assess the companys performance, additional KPIs such as revenue growth rate, gross margin, and operating margin should be examined. These metrics will provide insights into Harmonys ability to expand its top line, maintain pricing power, and manage its operating expenses.
HRMY Stock Overview
| Market Cap in USD | 1,493m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-08-19 |
HRMY Stock Ratings
| Growth Rating | -49.8% |
| Fundamental | 90.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.9% |
| Analyst Rating | 4.33 of 5 |
HRMY Dividends
Currently no dividends paidHRMY Growth Ratios
| Growth Correlation 3m | -77.5% |
| Growth Correlation 12m | -22% |
| Growth Correlation 5y | -30.1% |
| CAGR 5y | -19.94% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.29 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.48 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | -41.16 |
| Beta | 0.785 |
| Volatility | 42.32% |
| Current Volume | 558.6k |
| Average Volume 20d | 902.8k |
| Stop Loss | 24.9 (-3.9%) |
| Signal | -0.44 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (180.9m TTM) > 0 and > 6% of Revenue (6% = 46.4m TTM) |
| FCFTA 0.23 (>2.0%) and ΔFCFTA -1.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 66.17% (prev 47.52%; Δ 18.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 259.4m > Net Income 180.9m (YES >=105%, WARN >=100%) |
| Net Debt (-374.0m) to EBITDA (265.0m) ratio: -1.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.4m) change vs 12m ago 1.54% (target <= -2.0% for YES) |
| Gross Margin 78.34% (prev 77.60%; Δ 0.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 78.57% (prev 76.44%; Δ 2.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.04 (EBITDA TTM 265.0m / Interest Expense TTM 16.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.21
| (A) 0.46 = (Total Current Assets 691.4m - Total Current Liabilities 180.1m) / Total Assets 1.11b |
| (B) 0.08 = Retained Earnings (Balance) 87.6m / Total Assets 1.11b |
| (C) 0.25 = EBIT TTM 241.2m / Avg Total Assets 983.2m |
| (D) 0.26 = Book Value of Equity 87.8m / Total Liabilities 334.9m |
| Total Rating: 5.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 90.32
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 23.53% = 5.0 |
| 3. FCF Margin 33.49% = 7.50 |
| 4. Debt/Equity 0.22 = 2.48 |
| 5. Debt/Ebitda -1.41 = 2.50 |
| 6. ROIC - WACC (= 14.00)% = 12.50 |
| 7. RoE 26.32% = 2.19 |
| 8. Rev. Trend 94.60% = 7.10 |
| 9. EPS Trend -8.89% = -0.44 |
What is the price of HRMY shares?
Over the past week, the price has changed by -2.41%, over one month by -19.21%, over three months by -28.90% and over the past year by -25.94%.
Is Harmony Biosciences Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRMY is around 21.88 USD . This means that HRMY is currently overvalued and has a potential downside of -15.52%.
Is HRMY a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HRMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.9 | 69.5% |
| Analysts Target Price | 43.9 | 69.5% |
| ValueRay Target Price | 24.4 | -5.9% |
Last update: 2025-10-18 03:50
HRMY Fundamental Data Overview
P/E Trailing = 8.371
P/E Forward = 6.1275
P/S = 1.9326
P/B = 1.9915
Beta = 0.785
Revenue TTM = 772.5m USD
EBIT TTM = 241.2m USD
EBITDA TTM = 265.0m USD
Long Term Debt = 153.3m USD (from longTermDebt, last quarter)
Short Term Debt = 18.8m USD (from shortTermDebt, last quarter)
Debt = 172.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -374.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.10b USD (1.49b + Debt 172.1m - CCE 565.3m)
Interest Coverage Ratio = 15.04 (Ebit TTM 241.2m / Interest Expense TTM 16.0m)
FCF Yield = 23.53% (FCF TTM 258.7m / Enterprise Value 1.10b)
FCF Margin = 33.49% (FCF TTM 258.7m / Revenue TTM 772.5m)
Net Margin = 23.42% (Net Income TTM 180.9m / Revenue TTM 772.5m)
Gross Margin = 78.34% ((Revenue TTM 772.5m - Cost of Revenue TTM 167.3m) / Revenue TTM)
Gross Margin QoQ = 80.97% (prev 82.68%)
Tobins Q-Ratio = 0.99 (Enterprise Value 1.10b / Total Assets 1.11b)
Interest Expense / Debt = 2.12% (Interest Expense 3.65m / Debt 172.1m)
Taxrate = 19.87% (9.86m / 49.6m)
NOPAT = 193.3m (EBIT 241.2m * (1 - 19.87%))
Current Ratio = 3.84 (Total Current Assets 691.4m / Total Current Liabilities 180.1m)
Debt / Equity = 0.22 (Debt 172.1m / totalStockholderEquity, last quarter 773.1m)
Debt / EBITDA = -1.41 (Net Debt -374.0m / EBITDA 265.0m)
Debt / FCF = -1.45 (Net Debt -374.0m / FCF TTM 258.7m)
Total Stockholder Equity = 687.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.33% (Net Income 180.9m / Total Assets 1.11b)
RoE = 26.32% (Net Income TTM 180.9m / Total Stockholder Equity 687.4m)
RoCE = 28.69% (EBIT 241.2m / Capital Employed (Equity 687.4m + L.T.Debt 153.3m))
RoIC = 22.35% (NOPAT 193.3m / Invested Capital 864.9m)
WACC = 8.34% (E(1.49b)/V(1.67b) * Re(9.11%) + D(172.1m)/V(1.67b) * Rd(2.12%) * (1-Tc(0.20)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.36%
[DCF Debug] Terminal Value 75.30% ; FCFE base≈240.3m ; Y1≈252.8m ; Y5≈296.8m
Fair Price DCF = 74.69 (DCF Value 4.30b / Shares Outstanding 57.5m; 5y FCF grow 5.64% → 3.0% )
EPS Correlation: -8.89 | EPS CAGR: -15.03% | SUE: 1.37 | # QB: 1
Revenue Correlation: 94.60 | Revenue CAGR: 21.56% | SUE: -0.69 | # QB: 0
Additional Sources for HRMY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle